Alimera Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALIM research report →
Companyalimerasciences.com
Alimera Sciences, Inc. , a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- CEO
- Richard S. Eiswirth Jr.
- IPO
- 2019
- Employees
- 154
- HQ
- Alpharetta, GA, US
Price Chart
Valuation
- Market Cap
- $301.29M
- P/E
- -7.03
- P/S
- 3.73
- P/B
- 3.07
- EV/EBITDA
- -319.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.75%
- Op Margin
- -2.39%
- Net Margin
- -24.93%
- ROE
- -159.01%
- ROIC
- -1.46%
Growth & Income
- Revenue
- $80.75M · 49.19%
- Net Income
- $-20,132,000 · -11.18%
- EPS
- $-0.79 · 69.50%
- Op Income
- $-1,932,000
- FCF YoY
- -777.74%
Performance & Tape
- 52W High
- $5.65
- 52W Low
- $2.61
- 50D MA
- $5.56
- 200D MA
- $4.17
- Beta
- 1.25
- Avg Volume
- 866.83K
Get TickerSpark's AI analysis on ALIM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Kaseta Michael | sell | 1,825 |
| Sep 16, 24 | Kaseta Michael | sell | 50,000 |
| Sep 16, 24 | Snisarenko John | sell | 3,333 |
| Sep 16, 24 | Snisarenko John | sell | 46,150 |
| Sep 16, 24 | Snisarenko John | sell | 50,000 |
| Sep 16, 24 | Snisarenko John | sell | 6,000 |
| Sep 16, 24 | Snisarenko John | sell | 6,000 |
Our ALIM Coverage
We haven't published any research on ALIM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALIM Report →